Literature DB >> 20730473

A review of malignant meningiomas: diagnosis, characteristics, and treatment.

Simon Hanft1, Peter Canoll, Jeffrey N Bruce.   

Abstract

Anaplastic or malignant meningiomas (WHO Grade III) represent the most rare but aggressive subtype, accounting for 1-3% of all intracranial meningiomas. Due in large part to their scarcity, malignant meningiomas have been understudied and therefore represent an area where significant clinical advances may be made. To this point, our understanding of the genetic and histologic attributes of these lesions has grown, though the management and treatment of these aggressive tumors is less well elucidated and thus has room for further study. In this review, we describe the current understanding of malignant meningiomas in terms of their genetic alterations and unique histologic markers. Using this as a foundation, we will then discuss the current therapeutic strategies for managing these lesions and the future direction that such interventions may take.

Entities:  

Mesh:

Year:  2010        PMID: 20730473     DOI: 10.1007/s11060-010-0348-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  38 in total

1.  Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma.

Authors:  S Ozaki; T Nishizaki; H Ito; K Sasaki
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  p14ARF links the tumour suppressors RB and p53.

Authors:  S Bates; A C Phillips; P A Clark; F Stott; G Peters; R L Ludwig; K H Vousden
Journal:  Nature       Date:  1998-09-10       Impact factor: 49.962

3.  Role of diffusion tensor imaging in differentiating subtypes of meningiomas.

Authors:  M Jolapara; C Kesavadas; V V Radhakrishnan; B Thomas; A K Gupta; N Bodhey; S Patro; J Saini; U George; P S Sarma
Journal:  J Neuroradiol       Date:  2010-04-09       Impact factor: 3.447

4.  Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.

Authors:  J Boström; B Meyer-Puttlitz; M Wolter; B Blaschke; R G Weber; P Lichter; K Ichimura; V P Collins; G Reifenberger
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

5.  A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas.

Authors:  Arie Perry; Ruma Banerjee; Christine M Lohse; Bette K Kleinschmidt-DeMasters; Bernd W Scheithauer
Journal:  Brain Pathol       Date:  2002-04       Impact factor: 6.508

6.  Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy.

Authors:  E B Hug; A Devries; A F Thornton; J E Munzenride; F S Pardo; E T Hedley-Whyte; M R Bussiere; R Ojemann
Journal:  J Neurooncol       Date:  2000-06       Impact factor: 4.130

7.  Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.

Authors:  U M Schrell; M G Rittig; M Anders; U H Koch; R Marschalek; F Kiesewetter; R Fahlbusch
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

8.  Single voxel proton MR spectroscopy findings of typical and atypical intracranial meningiomas.

Authors:  Mustafa Kemal Demir; A Celal Iplikcioglu; Alp Dincer; Mahmut Arslan; Aydin Sav
Journal:  Eur J Radiol       Date:  2006-07-17       Impact factor: 3.528

9.  Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation.

Authors:  V A Nagar; J R Ye; W H Ng; Y H Chan; F Hui; C K Lee; C C T Lim
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-20       Impact factor: 3.825

10.  Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature.

Authors:  Stefan Wolfsberger; Soroush Doostkam; Hans-Gerd Boecher-Schwarz; Karl Roessler; Michael van Trotsenburg; Johannes A Hainfellner; Engelbert Knosp
Journal:  Neurosurg Rev       Date:  2004-05-27       Impact factor: 3.042

View more
  27 in total

1.  Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Authors:  David A Reardon; Andrew D Norden; Annick Desjardins; James J Vredenburgh; James E Herndon; April Coan; John H Sampson; Sridharan Gururangan; Katherine B Peters; Roger E McLendon; Julie A Norfleet; Eric S Lipp; Jan Drappatz; Patrick Y Wen; Henry S Friedman
Journal:  J Neurooncol       Date:  2011-09-22       Impact factor: 4.130

2.  Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.

Authors:  Emil Lou; Ashley L Sumrall; Scott Turner; Katherine B Peters; Annick Desjardins; James J Vredenburgh; Roger E McLendon; James E Herndon; Frances McSherry; Julie Norfleet; Henry S Friedman; David A Reardon
Journal:  J Neurooncol       Date:  2012-04-26       Impact factor: 4.130

3.  Atypical and anaplastic meningioma: outcomes in a population based study.

Authors:  T Garzon-Muvdi; W Yang; M Lim; H Brem; J Huang
Journal:  J Neurooncol       Date:  2017-04-20       Impact factor: 4.130

4.  Treatment-related secondary cancer in malignant meningiomas: a population-based study.

Authors:  Xuhui Bao; Lanfang Cao; Hailan Piao; Liyi Xie
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-08       Impact factor: 4.553

Review 5.  Pediatric meningioma: current approaches and future direction.

Authors:  Rishi S Kotecha; Reimar C Junckerstorff; Sharon Lee; Catherine H Cole; Nicholas G Gottardo
Journal:  J Neurooncol       Date:  2011-01-04       Impact factor: 4.130

Review 6.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

Authors:  Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum
Journal:  J Neurosurg       Date:  2015-01       Impact factor: 5.115

7.  Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas.

Authors:  Matthieu Peyre; Marc Zanello; Karima Mokhtari; Anne-Laure Boch; Laurent Capelle; Alexandre Carpentier; Stephane Clemenceau; Carine Karachi; Soledad Navarro; Aurelien Nouet; Vincent Reina; Charles-Ambroise Valery; Marc Sanson; Philippe Cornu; Michel Kalamarides
Journal:  J Neurooncol       Date:  2015-04-17       Impact factor: 4.130

8.  Papillary meningioma of the jugular foramen: A case report.

Authors:  Ying Yu; Haiyang Xu; Yubo Wang; Gang Zhao
Journal:  Oncol Lett       Date:  2015-10-08       Impact factor: 2.967

9.  Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539.

Authors:  C Leland Rogers; Arie Perry; Stephanie Pugh; Michael A Vogelbaum; David Brachman; William McMillan; Joseph Jenrette; Igor Barani; Dennis Shrieve; Andy Sloan; Joseph Bovi; Young Kwok; Stuart H Burri; Samuel T Chao; Aaron C Spalding; Mitchell S Anscher; Beatrice Bloom; Minesh Mehta
Journal:  Neuro Oncol       Date:  2015-10-22       Impact factor: 12.300

10.  Systematic Analysis of Outcomes for Surgical Resection and Radiotherapy in Patients with Papillary Meningioma.

Authors:  Christina Fong; Daniel T Nagasawa; Lawrance K Chung; Brittany Voth; Nicole Cremer; Kimberly Thill; Nolan Ung; Quinton Gopen; Isaac Yang
Journal:  J Neurol Surg B Skull Base       Date:  2015-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.